| Literature DB >> 33767008 |
Rokeia Eltheni1, Nikolaos Schizas1, Nektaria Michopanou1, Georgios Fildissis2.
Abstract
BACKGROUND: Life-long anticoagulant therapy is mandatory for patients who undergo heart valve replacement with implantation of a mechanical prosthesis. The aim of this study was to investigate the effects of a nurse-led patient educational program concerning oral anticoagulant therapy intake after heart valve replacement surgery on patients' knowledge of important parameters of anticoagulant administration.Entities:
Keywords: Anticoagulation Knowledge Assessment Questionnaire; Mechanical heart valve; Oral anticoagulant therapy; Patients' information; Personalized education
Year: 2021 PMID: 33767008 PMCID: PMC7946524 DOI: 10.5090/kjtcs.20.106
Source DB: PubMed Journal: J Chest Surg ISSN: 2765-1606
Satisfaction of the participants in the study and reasons for lack of satisfaction
| Variable | Category | Group | p-value | |
|---|---|---|---|---|
| Control | Intervention | |||
| Satisfaction with education received | No | 63 (63.0) | 20 (20.0) | <0.001 |
| Yes | 37 (37.0) | 80 (80.0) | ||
| If not, the reasons for a lack of satisfaction | More knowledge | 10 (10.0) | 0 | |
| More knowledge/instructions about the medicine | 19 (19.0) | 0 | ||
| More knowledge and time for discussion about the medicine | 1 (1.0) | 1 (1.0) | ||
| More knowledge and time for explanations | 1 (1.0) | 0 | ||
| More information | 12 (12.0) | 0 | ||
| More information and time for discussion about the medicine | 0 | 1 (1.0) | ||
| More information and time for explanations | 1 (1.0) | 0 | ||
| More time for discussion | 0 | 2 (2.0) | ||
| More time for education | 8 (8.0) | 16 (16.0) | ||
| More time for explanations | 9 (9.0) | 0 | ||
| More time for knowledge and explanations | 1 (1.0) | 0 | ||
Values are presented as number (%).
a)By Pearson χ2 test.
The socio-demographic and preoperative clinical characteristics of the participants
| Characteristic | Group | p-value | |
|---|---|---|---|
| Control | Intervention | ||
| Socio-demographic characteristics of patients | |||
| Age (yr) | 65.0±11.5 | 65.4±11.3 | 0.804 |
| Sex | 0.565 | ||
| Male | 61 (61.0) | 57 (57.0) | |
| Female | 39 (39.0) | 43 (43.0) | |
| Body mass index (kg/m2) | 27.2±4.4 | 28.1±4.5 | 0.154 |
| Educational level | 0.532 | ||
| Primary | 65 (65.0) | 72 (72.0) | |
| Secondary | 24 (24.0) | 18 (18.0) | |
| Tertiary | 11 (11.0) | 10 (10.0) | |
| Monthly income (euro) | 0.390 | ||
| <500 | 25.5 (25.0) | 34 (34.0) | |
| 500–1,000 | 53 (54.1) | 50 (50.0) | |
| >1,000 | 20 (20.4) | 16 (16.0) | |
| Clinical characteristics | |||
| Chronic disease | 0.514 | ||
| No | 73 (73.0) | 77 (77.0) | |
| Yes | 27 (27.0) | 23 (23.0) | |
| Preoperative antiplatelet or anticoagulant treatment (except acenocoumarol) | 1.000 | ||
| No | 67 (67.0) | 67 (67.0) | |
| Yes | 33 (33.0) | 33 (33.0) | |
| Diabetes mellitus | 0.617 | ||
| No | 75 (75.0) | 78 (78.0) | |
| Yes | 25 (25.0) | 22 (22.0) | |
| Chronic obstructive pulmonary disease | 0.341 | ||
| No | 81 (81.0) | 86 (86.0) | |
| Yes | 19 (19.0) | 14 (14.0) | |
Values are presented as mean±standard deviation or number (%).
a)By Pearson χ2 test.
INR measurements at FU examinations
| INR levels | Group | p-value | |
|---|---|---|---|
| Control | Intervention | ||
| 1-mo FU | |||
| Therapeutic | 25 (25.0) | 45 (45.0) | 0.011 |
| Low | 41 (41.0) | 32 (32.0) | |
| High | 34 (34.0) | 23 (23.0) | |
| 3-mo FU | |||
| Therapeutic | 47 (47.0) | 71 (72.4) | 0.001 |
| Low | 17 (17.0) | 13 (13.3) | |
| High | 36 (36.0) | 14 (14.3) | |
| 6-mo FU | |||
| Therapeutic | 76 (76.0) | 89 (90.8) | 0.014 |
| Low | 7 (7.0) | 1 (1.0) | |
| High | 17 (17.0) | 8 (8.2) | |
Values are presented as number (%). The participants were divided into 3 categories according to the achievement of the therapeutic goal.
FU, follow-up; INR, international normalized ratio.
a)By Pearson χ2 test.
Variation in INR levels at FU examinations: comparison between the control and intervention group
| Group | INR | p-value | p-value | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 mo | 3 mo | 6 mo | Variation | 1 mo vs. 3 mo | 3 mo vs. 6 mo | 1 mo vs. 6 mo | |||
| Control | 2.92±0.78 | 3.09±0.64 | 3±0.33 | 0.08±0.73 | 0.239 | 0.200 | 1.000 | 0.034 | |
| Intervention | 2.97±1.19 | 2.93±0.46 | 3±0.36 | 0.03±1.10 | 1.000 | 0.500 | 1.000 | - | |
| p-value | 0.775 | 0.050 | 0.917 | - | |||||
Values are presented as mean±standard deviation, unless otherwise stated. Differences in the variation from one measurement to the next between the 2 groups.
INR, international normalized ratio; FU, follow-up.
a)Difference between measurements. b)Repeated-measurements analysis of variance. c)Difference between 2 groups.
Percentage of patients who responded to more than 21 questions correctly
| Group | >21 correct answers | p-value | |||||
|---|---|---|---|---|---|---|---|
| 1 mo | 3 mo | 6 mo | 1 mo vs. 3 mo | 3 mo vs. 6 mo | 1 mo vs. 6 mo | ||
| Control | 12 (12.0) | 94 (94.0) | 99 (99.0) | <0.001 | <0.001 | 0.118 | |
| Intervention | 95 (95.0) | 99 (99.0) | 100 (100.0) | 0.212 | 0.059 | 1.000 | |
| p-value | 0.001 | 0.118 | 1.000 | ||||
Values are presented as number (%), unless otherwise stated.
a)For comparison between measurements (by Pearson χ2 test). b)For comparison between groups (by Pearson χ2 test).
Three-month incidence of hemorrhagic and thromboembolic episodes in each patient group
| Outcome | 3-mo incidence | p-value | |
|---|---|---|---|
| Control group (n=100) | Intervention group (n=100) | ||
| Hemorrhagic episodes | 14 (14.0) | 1 (1.0) | <0.001 |
| Thromboembolic episodes | 4 (4.0) | 3 (3.0) | 1.000 |
Values are presented as number (%), unless otherwise stated.
a)By Pearson χ2 test.